These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 24681743)

  • 1. Stage IIIC ovarian/peritoneal serous carcinoma: a heterogeneous group of patients with different prognoses.
    Bakkar R; Gershenson D; Fox P; Vu K; Zenali M; Silva E
    Int J Gynecol Pathol; 2014 May; 33(3):302-8. PubMed ID: 24681743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. International Federation of gynecology and obstetrics staging classification for cancer of the ovary, fallopian tube, and peritoneum: estimation of survival in patients with node-positive epithelial ovarian cancer.
    Pereira A; Pérez-Medina T; Magrina JF; Magtibay PM; Rodríguez-Tapia A; Peregrin I; Mendizabal E; Ortiz-Quintana L
    Int J Gynecol Cancer; 2015 Jan; 25(1):49-54. PubMed ID: 25405578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Restaging and Survival Analysis of 4036 Ovarian Cancer Patients According to the 2013 FIGO Classification for Ovarian, Fallopian Tube, and Primary Peritoneal Cancer.
    Rosendahl M; Høgdall CK; Mosgaard BJ
    Int J Gynecol Cancer; 2016 May; 26(4):680-7. PubMed ID: 26937751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymph Node Involvement Pattern and Survival Differences of FIGO IIIC and FIGO IIIA1 Ovarian Cancer Patients After Primary Complete Tumor Debulking Surgery: A 10-Year Retrospective Analysis of the Tumor Bank Ovarian Cancer Network.
    Gasimli K; Braicu EI; Nassir M; Richter R; Babayeva A; Chekerov R; Darb-Esfahani S; Sehouli J; Muallem MZ
    Ann Surg Oncol; 2016 Apr; 23(4):1279-86. PubMed ID: 26832880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serous carcinoma of the ovary and peritoneum with metastases to the breast and axillary lymph nodes: a potential pitfall.
    Recine MA; Deavers MT; Middleton LP; Silva EG; Malpica A
    Am J Surg Pathol; 2004 Dec; 28(12):1646-51. PubMed ID: 15577686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The new FIGO staging system for ovarian, fallopian tube, and primary peritoneal cancer.
    Zeppernick F; Meinhold-Heerlein I
    Arch Gynecol Obstet; 2014 Nov; 290(5):839-42. PubMed ID: 25082067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment and prognostic analysis of ovarian cancer patients with isolated region of lymph node recurrence].
    Tu H; Huang H; Huang QD; Li Z; Feng YL; Liu JH
    Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):928-33. PubMed ID: 23324194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymph node-positive stage IIIC ovarian cancer: a separate entity?
    Berek JS
    Int J Gynecol Cancer; 2009 Dec; 19 Suppl 2():S18-20. PubMed ID: 19955908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent developments on the significance and pathogenesis of lymph node involvement in ovarian serous tumors of low malignant potential (borderline tumors).
    Fadare O
    Int J Gynecol Cancer; 2009 Jan; 19(1):103-8. PubMed ID: 19258950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
    Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
    Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of lymph node ratio on survival in stage III ovarian high-grade serous cancer: a Turkish Gynecologic Oncology Group study.
    Ayhan A; Ozkan NT; Sarı ME; Celik H; Dede M; Akbayır Ö; Güngördük K; Şahin H; Haberal A; Güngör T; Arvas M; Meydanlı MM
    J Gynecol Oncol; 2018 Jan; 29(1):e12. PubMed ID: 29185270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymph node metastases as only qualifier for stage IV serous ovarian cancer confers longer survival than other sites of distant disease - a Swedish Gynecologic Cancer Group (SweGCG) study.
    Hjerpe E; Staf C; Dahm-Kähler P; Stålberg K; Bjurberg M; Holmberg E; Borgfeldt C; Tholander B; Hellman K; Kjølhede P; Högberg T; Rosenberg P; Åvall-Lundqvist E
    Acta Oncol; 2018 Mar; 57(3):331-337. PubMed ID: 29130381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphovascular space invasion and Ki67 as predictors of lymph node metastasis in primary low grade serous ovarian cancer.
    Grabowski JP; Glajzer J; Richter R; Plett H; Muallem MZ; Braicu EI; Taube E; Sehouli J
    Int J Gynecol Cancer; 2021 Jan; 31(1):98-103. PubMed ID: 33127866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of lymph node involvement in ovarian serous borderline tumors.
    Lesieur B; Kane A; Duvillard P; Gouy S; Pautier P; Lhommé C; Morice P; Uzan C
    Am J Obstet Gynecol; 2011 May; 204(5):438.e1-7. PubMed ID: 21349494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Construction and utilization of the prognostic model of serous ovarian adenocarcinoma].
    Yang R; Feng J; Fang XZ; Bai F; Cheng YX; Liu C; Zhu W; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2006 Jul; 41(7):459-63. PubMed ID: 17083811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The incidence of pelvic and para-aortic lymph node metastasis in uterine papillary serous and clear cell carcinoma according to the SEER registry.
    Mattes MD; Lee JC; Metzger DJ; Ashamalla H; Katsoulakis E
    J Gynecol Oncol; 2015 Jan; 26(1):19-24. PubMed ID: 25310855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ovarian papillary serous tumors of low malignant potential (serous borderline tumors). A long-term follow-up study, including patients with microinvasion, lymph node metastasis, and transformation to invasive serous carcinoma.
    Kennedy AW; Hart WR
    Cancer; 1996 Jul; 78(2):278-86. PubMed ID: 8674004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of survival outcomes in optimally and maximally cytoreduced stage IIIC ovarian high-grade serous carcinoma: Women with only peritoneal tumor burden versus women with both peritoneal and lymphogenous dissemination.
    Selcuk I; Meydanli MM; Yalcin I; Gungorduk K; Akgol S; Çelik H; Ayhan A
    J Obstet Gynaecol Res; 2019 Oct; 45(10):2074-2081. PubMed ID: 31373110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ZEB2 facilitates peritoneal metastasis by regulating the invasiveness and tumorigenesis of cancer stem-like cells in high-grade serous ovarian cancers.
    Li Y; Fei H; Lin Q; Liang F; You Y; Li M; Wu M; Qu Y; Li P; Yuan Y; Chen T; Jiang H
    Oncogene; 2021 Aug; 40(32):5131-5141. PubMed ID: 34211089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of Cox-2, CD34, Bcl-2, and p53 and survival in patients with primary peritoneal serous carcinoma and primary ovarian serous carcinoma.
    Khalifeh I; Munkarah AR; Lonardo F; Malone JM; Morris R; Lawrence WD; Ali-Fehmi R
    Int J Gynecol Pathol; 2004 Apr; 23(2):162-9. PubMed ID: 15084845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.